Q1e sales -2% y-o-y, orders +10%, adj. EBITA margin 6.
Enersense could release new financial targets as a pure service company on 28 April.
Q1 report Thursday, 24 April at 12:00 CET '25e-'27e EBITA down 3%; 6% CAGR in '24-'27e 11-9x EBITA i...
Report out 25 April at 07.00 CEST Q1e sales of EUR 45m +4% y-o-y, EBIT EUR 3.
Irisity AB (“Irisity” or “the Company”) is a leading provider of AI-driven video analytics solutions...
Redeye leaves its initial comments on Nanologica's Q1 report which came in largely as expected showi...
Redeye gives a short initial comment on the positive news that Leqembi has been approved in the EU.
Active Biotech räknar med att presentera resultat från den avslutade fas 1-studien på ögonsjukdom, d...
Redeye provides a short research update following Alzinova’s recent rights issue of approximately SE...
Ahead of Atria's Q1 report, we keep our group estimates largely intact.
Q-linea has improved access to growth capital and recently advanced the ASTar launch in Europe , the...
Momentum currently strong, but quarterly volatility remains EBIT cut 8% on weaker FX Share at 40x 20...
AVTECH presented its Q1 2025 figures, which closely aligned with Redeye’s projections for net sales,...
Redeye comments on the updated clinical guidelines regarding the use of LITT in patients with metast...
Q1e: a solid quarter with EBITA up 11% y-o-y Higher estimates following ambitious new targets Medica...
We expect Physitrack’s ongoing streamlining and consolidation efforts to begin bearing fruit in Q1 2...
Ahead of CapMan's Q1 2025 report due on 9 May, we revise our estimates to reflect expected fair valu...
Plejds nettoomsättning för det första kvartalet 2025 uppgick till 220,4 MSEK (159,0), en ökning med ...
Q-linea achieved its objective with five ASTar contracts during Q1, supported by a much-improved pip...
Report out 24 April Q1e sales of SEK 53m, -1% y-o-y, EBIT SEK -0.
